Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain
Por:
Font, R, Espinas, JA, Gil-Gil, M, Barnadas, A, Ojeda, B, Tusquets, I, Segui, MA, Margeli, M, Arcusa, A, Prat, A, Garcia, M, Borras, JM
Publicada:
9 oct 2012
Resumen:
AIMS: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in Catalonia.
MATERIALS AND METHODS: This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence measures and logistic regression to evaluate adherence-related risk factors.
RESULTS: The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa range: 0.018-0.267). Patients aged 50-74 years showed higher adherence than those aged <50 years. Adherence was also associated with: adjuvant chemotherapy and sequential hormonal therapy.
CONCLUSIONS: Concordance between the different measures was remarkably low, indicating the need for further research. Adherence is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice. British Journal of Cancer (2012) 107, 1249-1256. doi:10.1038/bjc.2012.389 www.bjcancer.com Published online 6 September 2012 (C) 2012 Cancer Research UK
Filiaciones:
Font, R:
Catalonian Reg Author, Dept Hlth, Catalonian Canc Strategy Unit, Barcelona 08908, Spain
Univ Barcelona, Dept Clin Sci, Bellvitge Biomed Res Inst, Barcelona 08907, Spain
Espinas, JA:
Catalonian Reg Author, Dept Hlth, Catalonian Canc Strategy Unit, Barcelona 08908, Spain
Gil-Gil, M:
Catalonian Inst Oncol, Dept Med Oncol, Bellvitge Biomed Res Inst, Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08908, Spain
Barnadas, A:
Santa Creu & Sant Pau Hosp, Dept Med Oncol, Barcelona 08025, Spain
Ojeda, B:
Santa Creu & Sant Pau Hosp, Dept Med Oncol, Barcelona 08025, Spain
Tusquets, I:
Hosp del Mar, Dept Med Oncol, Barcelona 08003, Spain
Segui, MA:
Parc Tauli Hlth Corp, Dept Med Oncol, Sabadell 08208, Spain
Margeli, M:
Hosp Badalona Germans Trias & Pujol, Dept Med Oncol, ICO Badalona, Badalona 08916, Spain
Arcusa, A:
Terrassa Hlth Consortium, Dept Med Oncol, Terrassa 08227, Spain
Prat, A:
Catalonian Reg Author, Dept Hlth, Catalonia Hlth Serv, Barcelona 08028, Spain
Garcia, M:
Catalonian Inst Oncol, Bellvitge Biomed Res Inst, Canc Prevent & Control Grp, IDIBELL, Barcelona 08908, Spain
Borras, JM:
Catalonian Reg Author, Dept Hlth, Catalonian Canc Strategy Unit, Barcelona 08908, Spain
Univ Barcelona, Dept Clin Sci, Bellvitge Biomed Res Inst, Barcelona 08907, Spain
Green Published, Hybrid Gold
|